Please ensure Javascript is enabled for purposes of website accessibility

China Reports No New Coronavirus Outbreaks, First Time Since Outbreak Began

By Mark Prvulovic - Mar 19, 2020 at 4:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus cases in the country seem to have stabilized.

For the first time since the COVID-19 pandemic began back in January, China has reported no new locally transmitted infections. At a news conference on Thursday, officials from China's National Health Commission said that although there had been 34 new cases in the past 24 hours, all of them came from people who were recent overseas arrivals.

Although the country has faced significant criticism regarding how it handled the initial outbreak, since China chose to quarantine the province of Hubei, the number of cases in the country has stabilized around 81,000.

In comparison, countries like Italy, Spain, Germany, France, and even the U.S. still haven't seen a slowdown in new cases. If outbreaks in these countries don't slow down, Italy could end up surpassing China in terms of total COVID-19 cases in as little as a week.

A person holding a COVID-19 test in front of a Chinese and an American flag.

Image source: Getty Images.

The Chinese government is also tightening its quarantine measures on international arrivals in order to prevent further outbreaks. All overseas passengers will be placed in collective quarantine at specified facilities until they are deemed to be safe.

Potential treatments

One of the leading COVID-19 candidates being researched right now, an antiviral drug from Gilead Science (GILD 0.89%) called remdesivir, is undergoing multiple late-stage clinical trials in China. Remdesivir is also one of the potential treatments that President Trump specifically mentioned during a press briefing on Thursday.

While remdesivir helps treat symptoms of COVID-19, other biotech companies are working on preventative vaccines that would immunize someone from the virus. Both Moderna and Inovio Pharmaceuticals have vaccine candidates that have begun early clinical testing in humans.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.36 (0.89%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.